New York, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Viral and Non-Viral Vector Manufacturing Market: Focus on Vector Type, Application, Disease and ...

Ottawa, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The global viral vector and plasmid DNA manufacturing market size was valued at USD 7.19 billion in 2024 and is expected to be worth around USD 46.02 billion ...

Pharmaceutical Technology spoke with Colleen Floreck, vice president, Global Marketing and Strategy, Catalent Cell and Gene Therapy about the specific requirements and challenges for expanding ...

The Viral Vector and Plasmid DNA Manufacturing Market refers to the industrial processes and services that enable the production of viral vectors and plasmid DNA used in gene therapies, vaccine ...

The global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...

G-CON will provide a complete cleanroom infrastructure for GE Healthcare’s cell therapy and viral vector production platforms that will simplify early-stage manufacturing efforts. G-CON Manufacturing, ...

SAN DIEGO & COLUMBUS, Ohio--(BUSINESS WIRE)--Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a ...

Lentiviral vectors (LVVs) have proven to be extremely versatile genetic delivery vehicles, gaining space as a gene transfer technology tool used both for cell and gene therapies. They are utilised for ...

Partnership to Bolster Solid Biosciences’ Gene Therapy Pipeline, Including AAV Process Development, Scale Up and cGMP Manufacturing Services Forge will provide an adeno-associated viral (AAV) vector ...

CAMBRIDGE, Mass. & COLUMBUS, Ohio--(BUSINESS WIRE)--Solid Biosciences Inc. (Solid, Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy ...